


## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

# Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342

## **Provisional Stakeholder List**

| Consultees   | Commentators (no right to submit or                                  |
|--|--|
|  | appeal)  |
| Company  | <u>General</u>   |
| Pfizer (marstacimab)   | <ul> <li>All Wales Therapeutics and Toxicology</li> </ul>            |
|  | Centre   |
| Patient/carer groups   | <ul> <li>Allied Health Professionals Federation</li> </ul>           |
| Black Health Agency for Equality   | <ul> <li>Board of Community Health Councils in</li> </ul>            |
| Gene People  | Wales  |
| Genetic Alliance UK  | <ul> <li>British National Formulary</li> </ul>                       |
| Haemophilia Society  | <ul> <li>Care Quality Commission</li> </ul>                          |
| Immunodeficiency UK  | <ul> <li>Cell and Gene Therapy Catapult</li> </ul>                   |
| South Asian Health Foundation  | <ul> <li>Department of Health, Social Services</li> </ul>            |
| Specialised Healthcare Alliance  | and Public Safety for Northern Ireland                               |
|  | Haemophilia Scotland   |
| Healthcare professional groups   | Haemophilia Wales  |
| Association of Genetic Nurses &  | <ul> <li>Healthcare Improvement Scotland</li> </ul>                  |
| Counsellors  | <ul> <li>Hospital Information Services -</li> </ul>                  |
| British Blood Transfusion Society  | Jehovah's Witnesses  |
| British Committee for Standards in   | Medicines and Healthcare products                                    |
| Haematology  | Regulatory Agency  |
| British Geriatrics Society   | National Association of Primary Care                                 |
| British Paediatric Allergy, Immunity      And Infantian Converse                             | National Pharmacy Association  |
| and Infection Group  | NHS Confederation  |
| British Society for Gene and Cell Thereny  | Scottish Medicines Consortium  |
| Therapy  | Welsh Government   |
| British Society for Genetic Medicine     British Society for Hoometology                     | Welsh Health Specialised Services                                    |
| British Society for Haematology     British Society of Medical Constinut                     | Committee  |
| British Society of Medical Genetics     Haemophilia Nurses Association                       | Possible comparator companies  |
|  | Possible comparator companies  |
| <ul> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> </ul> | <ul> <li>Bio Products Laboratory (factor IX, factor VIII)</li> </ul> |
| Royal College of National     Royal College of Pathologists                                  | CSL Behring (etranacogene  |
| <ul> <li>Royal College of Physicians</li> </ul>  | dezaparvovec, factor IX, factor VIII)                                |
| <ul> <li>Royal College of Thysicians</li> <li>Royal Pharmaceutical Society</li> </ul>        | Grifols UK (factor IX, factor VIII)                                  |
| <ul> <li>Royal Frialmaceutical Society</li> <li>Royal Society of Medicine</li> </ul>         | Novo Nordisk Ltd (factor VIII)                                       |
| UK Clinical Pharmacy Association   | alpha, nonacog beta pegol turoctocog                                 |
| UK Forum on Haemoglobin Disorders  | alfa pegol)  |



| Consultees   | Commentators (no right to submit or appeal)  |
|--|--|
| <ul> <li>UK Haemophilia Centre Doctors'<br/>Organisation</li> <li>Others</li> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul> | <ul> <li>Octapharma (factor VIII, simoctocog alfa)</li> <li>Pfizer (fidanacogene elaparvovec, moroctocog alfa, nonacog alfa)</li> <li>Roche (emicizumab)</li> <li>Swedish Orphan Biovitrum (efmoroctocog alfa, eftrenonacog alfa)</li> <li>Takeda (factor IX, octocog alfa, rurioctocog alfa pegol, susoctocog alfa)</li> </ul>  |
|  | <ul> <li>Relevant research groups</li> <li>Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>Cochrane Haematology</li> <li>Cochrane UK</li> <li>Genomics England</li> <li>Haemnet</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>NHS Oxford Haemophilia and Thrombosis Centre</li> <li>NHS Southern Haemophilia Network</li> </ul> |
|  | <ul><li>Associated Public Health groups</li><li>Public Health Wales</li><li>UK Health Security Agency</li></ul>  |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342 Issue date: January 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.